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ABSTRACT 
 
Recent advances in pharmaceutical manufacturing techniques are showing the promise of continuous 
production, and pharmaceutical firms, currently reliant on mature batch technology, are beginning to 
turn toward Continuous Pharmaceutical Manufacturing (CPM).  Continuous production techniques 
have efficiency, cost, reliability and quality advantages: in this paper we evaluate and quantify these 
for the case of the CPM of artemisinin, a key antimalarial Active Pharmaceutical Ingredient (API).  
Published reaction and unit operation data are analysed, static models developed, and continuous plug 
flow reactors designed for a reference case producing 100 kg of API per year: the small reactor 
volumes computed (19.72 mL and 78.72 mL) illustrate one benefit of continuous techniques, that of 
small equipment footprint.  In addition, alternative CPM cases are also computed whereby different 
continuous API recovery operations are evaluated in comparison to the base case; the latter employs a 
reported batch product recovery.  Utilising published solubility data as well as data estimated using 
the UNIFAC method, systematic evaluation identifies ethanol (EtOH) and ethyl acetate (EtOAc) as 
good candidate anti-solvents for continuous crystallisation.  For the same 100 kg per year production 
level of API, designs using continuous separation techniques can achieve significantly improved E-
factor values (22.52 average) compared to the batch process (65.28), implying enhanced sustainability 
through reduced waste generation.  This API of critical societal importance is a good candidate for 
CPM, with the future benefits of performing full analysis and technoeconomic optimisation evident. 
 
Highlights: 
 
 Historic analysis of artemisinin price, production and market demand. 
 Novel kinetic data analysis and reactor design for complex organic reactions in flow. 
 Systematic evaluation of antisolvents for continuous product separation schemes. 
 Ethanol and ethyl acetate emerge as good candidates for continuous crystallisation. 
 Continuous designs generate 66.2% less waste (lower E-factors) than reference batch case. 
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1 INTRODUCTION 
Driven by market and technological drivers including increasing R&D costs and competition from 
generic manufacturers (Behr et al., 2004; Jolliffe and Gerogiorgis, 2015a), the paradigm of batch 
manufacturing, the predominant method of pharmaceutical production, is being challenged by recent 
work in the field of Continuous Pharmaceutical Manufacturing (CPM) which has gained support at 
the highest regulatory levels (Plumb, 2005; Lee et al., 2015).  Batch process efficiency can be very 
low, with high rates of waste production and solvent use, while inherently poor heat and mass transfer 
lead to difficulties in process scale-up (Anderson, 2012; Gernaey et al., 2012).  In contrast, continuous 
production methods offer higher yields, smaller equipment, more efficient solvent and energy use, and 
safer, more reliable operation (Roberge et al., 2008; Anderson, 2012); industries such as the 
petrochemicals sector have benefited from the advantages of continuous processing for many years 
(Schaber et al., 2011).   
Investigating the feasibility and viability of CPM processes via process modelling and simulation is 
a rapid and cost-efficient methodology which can be used to quantitatively evaluate the benefit and 
potential of continuous processes for pharmaceutical production (Gerogiorgis and Ydstie, 2005; 
Gerogiorgis and Barton, 2009; Teoh et al., 2015); furthermore, elaborate design and optimisation of 
multiphase unit operations are also possible, given the vast computational power and robust software 
now available for high-fidelity simulations (Gerogiorgis and Ydstie, 2003; Gerogiorgis et al., 2003). 
High-resolution model-based control studies thus advance the state of the art (Nayhouse et al., 2015). 
We have previously shown how systematic analysis can identify good candidates for CPM, and 
have performed initial technoeconomic comparisons of the CPM of two key Active Pharmaceutical 
Ingredients (API), ibuprofen and artemisinin (1) (Jolliffe and Gerogiorgis, 2015a, 2015b).  Here, we 
present in detail a more in-depth model and steady state simulation of the continuous production of 
artemisinin, one of the most effective anti-malarial APIs available today.  The flowsheet used is 
adapted from published continuous chemical synthesis routes, the kinetics of which have been 
analysed and used for systematic reactor design (Kopetzki et al., 2013). 
Malaria is a disease of extreme importance.  There are an estimated 225 to 500 million annual cases 
of malaria from Plasmodium falciparum (the main strain of malaria-causing parasite), resulting in 
approximately one million deaths, while P. vivax (a strain causing marginally more benign but still 
potentially fatal symptoms) causes 70 to 390 million cases a year.  It disproportionately affects low-
 
Fig. 1.  Historic and projected artemisinin market data (The Boston Consulting Group, 2009; Bionexx, 2014).   
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income regions and young children, and has significant detrimental effects on economies through lost 
productivity (Davis et al., 2011).  Present mainly in tropical regions, it can be found in Central and 
South America, large areas of Asia and Africa, the Caribbean, and the Middle East. 
Artemisinin and its medicinal and therapeutic properties (White, 2008) have long been known: the 
natural source of artemisinin, the plant sweet wormwood (Artemisia annua), has featured in 
traditional Chinese medicine for at least two millennia, and an early reference to its use in treating 
malaria can be found in a medical text from 1596 (Tu, 2011; Henry, 2014).  Known in Chinese as 
qinghao, artemisinin was first isolated and identified as a result of a project to find cures and 
treatments for malaria (Tu et al., 1981; Tu et al., 1982).  The 2015 Nobel Prize in Physiology or 
Medicine was awarded to Youyou Tu for her discovery of artemisinin (The Nobel Assembly, 2015). 
Artemisia annua is native to temperate regions of Asia, but can now be found in various other 
locations with suitable climactic conditions; main cultivation and production centres are China (180-
200 tonnes of artemisinin in 2011), Vietnam (23-26 tonnes), Madagascar (16 tonnes were projected 
for 2013) and East Africa (Kenya and Uganda, 14 tonnes projected for 2013) (Cutler, 2013).  Other 
minor producers include India, Australia, Papua New Guinea, West Africa, Brazil, Argentina, UK, 
USA, and Switzerland (Ellmann, 2010).  Current production methods are predominantly plant 
cultivation and subsequent batch extraction, a process which has long lead times between 12−14 
months (seed planting to API extraction) (Hommel, 2008).  In conjunction with the fluctuating and 
unpredictable artemisinin demand (e.g. malaria is transmitted by mosquitos, the levels of which can 
be significantly affected by weather) this leads to highly variable prices: from 2007 to 2011 it was 
between $200-$400 per kilogram, rising to $900 at the end of 2011 (due to shortages from poor 
harvests) before dropping again to $400 in 2012, and to $360 at the start of 2013 (Cutler, 2013).  
Indeed, comparisons of global monthly artemisinin prices and production levels illustrate periods of 
over production (2007, 2014) caused by price peaks several years prior (2005, 2012) (Fig. 1). 
In anti-malaria medications, artemisinin derivatives are often used to enhance bioavailability, and 
these are often used in conjunction with other antimalarial substances in Artemisinin Combination 
Therapies (ACT), and it is these which constitute the majority of formulations that are sold.  The 
artemisinin derivative targets the bulk of the parasitic infection within the first three days, with the 
partner substance targeting residual parasite levels (World Health Organisation, 2015).  Examples of 
derivatives include artesunate (water-soluble), artemether (lipid-soluble) and artemotil (Miller and Su, 
2011), while partner anti-malarial substances they are often combined with include lumefantrine, 
amodiaquine, mefloquine, piperaquine and pyronaridine.  The range of subtances available is also 
beneficial in delaying the onset of resistance of the parasites to the medication. 
The Global Fund reports that, in the 2008 to 2014 period, the anti-malarial market was worth $340 
million with two categories of ACTs – artemether-lumefantrine (AL) and artesunate-amodiaquine 
 
Fig. 2. Conceptual flowsheet for continuous production of artemisinin (adapted from Kopetzki et al., 2013). 
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(ASAQ) – collectively constituting 87% of this.  There are five main pharmaceutical firms involved: 
Novartis and Ajanta producing AL, Sanofi Aventis producing ASAQ, and Ipca and Cipla producing 
both forms (Bionexx, 2014). 
Demand for ACTs can be highly variable (The Boston Consulting Group, 2009), and although 
artemisinin price fluctuations have an impact on the costs to firms producing ACTs, due to the 
moderately low impact of artemisinin value on the ACT selling price.  For eight major ACT 
formulations (four AL, four ASAQ), constituting 354 million treatments at 292 million USD (average 
ACT price 0.82 USD per dose), artemisinin constituted between 20-23% of cost for AL formulations 
and between 10-29% for ASAQ formulations, an average of 21%, minimizing somewhat the cost to 
end purchasers (Bionexx, 2014). 
In recent years, there have been attempts to produce synthetic (Zhu and Cook, 2012) and semi-
synthetic (Paddon et al., 2013; Peplow, 2013; Paddon and Keasling, 2014; Turconi et al., 2014) 
artemisinin by a variety of methods in order to stabilise production levels, including the use of 
biotechnology (Hommel, 2008; Wang et al., 2014; Abdin and Alam, 2015; Corsello and Garg, 2015).  
Of particular interest is the recent demonstration of the continuous synthesis for this key 
pharmaceutical from the waste material from one of the current batch extraction processes (Lévesque 
and Seeberger, 2012; Kopetzki et al., 2013).  Dihydroartemisinic acid (DHAA, 2) is normally 
discarded as waste: in the process developed by Kopetzki et al., (2013), on which this work is based, 
photo-oxidation with the subsequent use of acid catalyst is used to transform 2 via several 
intermediates to artemisinin.  Further developments of this process have been reported to produce 
various artemisinin derivatives, and there are plans to commercialise the process (Extance, 2012; 
Gilmore et al., 2014; Seeberger et al., 2014).  Other groups are also pursuing similar routes: strategies 
applying Green Chemistry principles to continuous artemisinin synthesis involving liquid CO2 solvent 
with catalysts, as well as synthesis using benign, simple solvents (ethanol and water), are being 
explored (Amara et al., 2015). 
Product recovery and crystallisation is a well-established operation, and is used in many industries, 
in both batch and continuous operation; the latter is predominantly used for the largest scale processes 
(Ward et al., 2011).  In recent years, there have been advances in the study of the continuous 
crystallisation of APIs using both well-mixed (Kwon et al., 2014a) and plug-flow (Kwon et al., 
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Fig. 3. Reaction scheme detailing synthesis path from feed material 2 to product API 1 and side products via 
intermediates (Kopetzki et al., 2013). 
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2014b) crystallisers.  Although few in number at this stage, there have been demonstrations of 
continuous API crystallisation in pilot plants (Zhang et al., 2014). 
Process control in continuous pharmaceutical operations is of course of paramount importance.  For 
continuous crystallisation control key process parameters include crystal size and shape, and toward 
this process modelling has been frequently successful (Griffin et al., 2010; Kwon et al., 2013).  Very 
recently, implemented (i.e. model-free) plantwide control for a CPM process has been demonstrated, 
also incorporating crystallisation (Lakerveld et al., 2014).  The modelling and control of a novel 
dropwise additive manufacturing process for pharmaceutical products (DAMPP) has also been 
reported (Içten et al., 2015). 
This paper is organized in the following manner: first, the process flowsheets and reactions are 
Table 1. Main component molar and mass flow changes due to all three continuous flow reactions. 
 
Component Stoichiometric 
coefficient 
Selectivity Flow in  Flow change       Flow out 
(%) (mmol hr−1) (g hr−1) (mmol hr−1) (g hr−1) (mmol hr−1) (g hr−1) 
PFR 1         
2 (DHAA) −1  98.59 23.30 −96.62 −22.84 1.97 0.47 
O2 −1  318.18 10.18 −96.62 −3.09 221.56 7.09 
3 +1 86.6a 0 0 +83.67 +22.45  83.67 22.45 
4 +1 10.3a 0 0 +9.96 +2.67  9.96 2.67 
5 +1 3.1a 0 0 +2.99 +0.80  2.99 0.80 
PFR 2         
2 (DHAA) − − 1.97 0.47 − − 1.97 0.47 
O2 −1 − 221.56 7.09 −62.56 −2.00 158.99 5.09 
3 −1 − 83.67 22.45 −69.87 −18.75 13.81 3.70 
4 −1 − 9.96 2.67 −6.10 −1.64 3.86 1.04 
5 − − 2.99 0.80 − − 2.99 0.80 
6 +1 100.0c 0 0 +6.10 +1.53 6.10 1.53 
7 +1 6.7b 0 0 +4.66 +1.09 4.66 1.09 
10 +1 3.8b 0 0 +2.65 +0.66 2.65 0.66 
         
1(API) +1 89.5b 0 0 +62.56 +17.66 62.56 17.66 
Table 2. Process mass balance (g hr−1). 
 Stream 
Component F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
2 (DHAA) 23.30  0  0  23.30 0 23.30 0 23.30 0.47 0.47 
1 (API) 0 0 0 0 0 0 0 0 0 17.66 
DCA 0 0.11 0 0.11 0 0.11 0 0.11 0.11 0.11 
TFA 0 0 5.62  5.62 0 5.62  0 5.62  5.62  5.62  
O2 0 0 0 0 0 0 10.18 10.18 7.09 5.09 
3 0 0 0 0 0 0 0 0 22.45 3.70 
4 0 0 0 0 0 0 0 0 2.67 1.04 
5 0 0 0 0 0 0 0 0 0.80 0.80 
6 0 0 0 0 0 0 0 0 0 1.53 
7 0 0 0 0 0 0 0 0 0 1.09 
10 0 0 0 0 0 0 0 0 0 0.66 
H2O2 0 0 0 0 0 0 0 0 0 0.16 
H2O 0 0 0 0 0 0 0 0 0 1.28 
Toluene 0 0 0 0 168.27 168.27 0 168.27 168.27 168.27 
Total  23.30 0.11 5.62 29.04 168.27 197.30 10.18 207.48 207.48 207.48 
5 
introduced, before kinetic data analysis and parameter estimation is covered along with process mass 
balances and plug flow reactor design methodology. The process for the design of continuous 
separations is given next, before results for mass balances, reactor designs and separations are 
evaluated in relation to typical performances for pharmaceutical processes.  Detailed models for the 
calculation of API solubilities by the UNIFAC method are given in the Appendix. 
2 FLOWSHEET AND PROCESS MODELLING 
The flowsheet is based on a recent proven continuous synthesis route (Fig. 2) (Kopetzki et al., 2013).  
Artemisinin is produced in a series of two plug flow reactors, the first reactor being a chilled photo-
oxidation reactor operating at −20°C.  Here, raw material 2 (DHAA) is photo-oxidised (Shenck ene 
reaction) to key intermediate 3.  DCA (9,10-dicyanoanthracene) is a photosensitiser, essential to allow 
the production of the singlet oxygen necessary for the photooxidation reaction; light is provided by a 
suitable source such as a high-power mercury lamp (Kopetzki et al., 2013).  Intermediate 4 and by-
product 5 are also produced (Fig. 3). 
Subsequently in PFR2, a variety of reactions and transformations occur.  Intermediate 3 (with 
trifluoroacetic acid – TFA – acting as acid catalyst) produces side product 7 by proximal protonation; 
terminal protonation results in a Hock rearrangement leading to 9, which in turn either transforms into 
byproduct 10 via isomerisation or reacts with triplet oxygen to produce the API artemisinin (1).  Other 
minor byproducts include hydrogen peroxide (H2O2, the loss of which leads to 7) and water (the loss 
of which leads to 6, 10 and 1) (Gilmore et al., 2013).  A dehydrating cyclisation of 4 produces 
byproduct 6; in some conditions, 5 may further react, but negligible amounts are present under the 
operating conditions studied here (Kopetzki et al., 2013). 
PFR reactor design requires the calculation of the process mass balances (Table 1, Table 2).  The 
starting point is a recent synthesis study (Kopetzki et al., 2013), with the following assumptions: 1) 
reactions occur only inside the PFR reactors and not in any of the lines connecting them, 2) isothermal 
operation is ensured in all reactors via suitable heating media, 3) temperature changes cause no phase 
transformation or precipitation affecting the flow, 4) reactions shown in Fig. 3 are the only ones 
which occur, 5) gas-to-liquid mass transfer in in the reactors is not limiting and does not impede the 
reactions in any way. 
3 KINETIC PARAMETER ESTIMATION AND REACTOR DESIGN 
The reactions for the CPM of artemisinin have been assumed to be first-order given the nature of the 
reactions (large organic molecules reacting with excess of smaller reagents, e.g. O2); data was 
available for these reactions (Kopetzki et al., 2013; Seeberger et al., 2014).  Kopetzki et al. (2013) 
employed pure oxygen supplied at 10 bar with a volumetric flow at the inlet of 5 mL min−1, 
corresponding to 3.2 equivalents with respect to feed DHAA, reducing to 1.9 mL min−1 (at 10 bar) 
after all reactions are complete, implying a feed oxygen excess of 61.2%.  Experimental 
measurements of oxygen solubility in toluene indicate saturated O2 concentrations of 0.65% and 
0.84% at −20°C and 25°C , respectively, at 10 bar (corresponding to Henry’s constant values of 154.8 
MPa and 118.4 MPa – determined from literature) (Li et al., 2007; Wu et al., 2014).  Good mixing 
that is achievable with small process line and reactor dimensions, and high interfacial area (up to 
25,300 m2/m3), can ensure that the reaction is not impeded and for a first-order assumption to hold 
(Seeberger et al., 2014). 
Reaction rate constants have been estimated based on stated conversions and lab-scale reaction line 
volumes, with mathematical programming used to find rate constant values.  Reciprocals of 
instantaneous reaction rates can be plotted against conversion, assuming a given value for the rate 
constant, and necessary reactor volumes can be determined from the area under the curve, as this 
corresponds to reactor volume over the product of volumetric flow and inlet reactant concentration.  
Nonlinear optimisation allows the determination of necessary values of the rate constant for calculated 
reactor volumes to match the experimental reactor volumes. 
In the first PFR, the photo-oxidation reaction can achieve 98% conversion of 2 (DHAA), with 
product selectivities of 86.6% (3), 10.3% (4) and 3.1% (5) (Table 3), with the aforementioned kinetic 
data analysis implying a rate constant of 39.12 hr−1; this is for the reaction conducted at −20°C 
(Kopetzki et al., 2013).  This agrees well with additional data (Fig. 4A), with a value of 38.8 hr−1 for 
6 
the same reaction at −18°C (Table 4) (Seeberger et al., 2014).  It can be seen that the rate constant has 
very non-monotonic behaviour and high variability with respect to temperature: this is as 
experimental data indicates highly variable non-monotonic conversions with respect to temperatre, 
although desired product selectivity is monotonic, increasing with decreasing temperature (see page 
32, Table 4 in the publication of Seeberger et al. (2014)).  The continuous line is a linear best fit of 
data with conversions explicitly given for different reaction times (see page 32, Table 3 in the 
publication of Seeberger et al. (2014)), with the rate constant (65.5 hr−1) determined from the slope.  
An outlying data point at t = 0.051 hr (not shown) has been discounted: this fell significantly below 
the trend, implying higher reactant consumption than expected.  A possible explanation is that the 
higher reaction time allowed sufficient temperature increases for higher conversions (cooling is 
required to maintain temperatures) (Seeberger et al., 2014). 
For the dashed lines in Fig. 4A the rate constants have been determined using nonlinear 
optimisation.  Although a different solvent (dichloromethane, DCM) and photosensitizer (tetraphenyl 
porphyrin, TPP) were used in these cases, similar yet better conversions and selectivities can be 
achieved using toluene and DCA, ensuring that the use of kinetic parameters determined from the 
DCM and TPP data will give marginally over-designed reactors (Seeberger et al., 2014). 
For the second reaction (mutliple transformations beginning with intermediate 3 and resulting in 1, 
artemisinin) a conversion has been calculated based on data for the reaction conducted in batch at 
small scale (5 mL total volume) for a duration of 20 minutes (Fig. 4B) (Kopetzki et al., 2013; 
Seeberger et al., 2014).  The reported yields (based on the original quantity of  2) of 1, 7, and 10 are 
59.1%, 4.4%, and 2.5%, respectively.  In conjunction with data for the conversion of 2 (DHAA) in the 
first PFR, a 78% conversion of 3 in the second PFR can be estimated from these values, with product 
selectivities of 89.5%, 6.7%, and 3.8% (for 1, 7 and 10, respectively).  Employing a similar analysis 
as for the photoxidation reaction gives 4.502 hr−1 for the rate constant, which again shows significant 
variability and non-monotonicity.  Subsequently applying this value for the stated reaction time in 
continuous flow (24 minutes, 0.4 hours in the 25°C reactor) increases conversion of 3 to 83.5% 
(Seeberger et al., 2014). 
Using reported data, the conversion of intermediate 4 (67.0%) was similarly calculated using the 
overall yield of byproduct 6 (6.1%, based on initial DHAA amount) (Kopetzki et al., 2013).  
Byproduct 6 is not of commercial interest here but must be taken into account in determining 
byproduct and impurity levels, key in final API separation operations and product quality and purity 
requirements. 
Kopetzki et al. (2013) report small quantities of unspecified by-product from the photo-oxidation 
reaction.  At less than 1% by moles, these have been assumed negligible, and the values for selectivity 
  
Fig. 4. Determination of rate constant used in this design. A: DHAA photooxidation (Table 3) (Seeberger et al., 
2014).  B: Reaction of intermediate 3 (Table 4) (Seeberger et al., 2014). 
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given here have been adjusted slightly to account for the difference.  For the reactions occurring in the 
second PFR, the balance of yield based on initial DHAA is assumed to be unreacted species 3.  For 
PFR design, small internal diameters of 5 mm have been studied to ensure adequate heat transfer; 
proven CPM systems with designs at this length scale have been reported (Mascia et al., 2013). 
The PFRs presented here have been designed using the standard plug flow reactor performance 
equation for a first-order reaction: 
 
fAX
A
A
Ai
r
dX
C
,
0
0,  (1) 
The static model assumes homogeneous mixtures and ideal solutions with isothermal operation.  
The PFRs are assumed to be submerged in well circulating heat transfer media that ensures that there 
are no temperature gradients, with specific heat capacities and reaction enthalpies remaining constant; 
phase change also does not occur.  There are also no radial concentration gradients, and mass transfer 
between the gaseous O2 component and the liquid stream is assumed to not be reaction limiting.  The 
small PFR dimensions considered ensure that the assumptions of excellent heat and mass transfer 
remain valid. 
4 FINAL SEPARATION 
The continuous synthesis route shown here will produce a range of organic intermediates and 
byproducts which must be removed in final purification separation.  In the lab-scale demonstration of 
this continuous synthesis, multiple batch operations were used, consisting of extraction, evaporation, 
filtration, recrystallisation, and washing stages (Kopetzki et al., 2013; Seeberger et al., 2014).  
Suitable continuous separation alternatives must be found to fully capitalize on and demonstrate the 
benefits of CPM.  Furthermore, for further processing the product API is required in pure solid form 
for downstream operations and final formulation (unless it will be used to produce artemisinin 
derivatives). 
The reported efficiencies of the batch separation scheme used by Kopetzki et al. (2013) have been 
used to determine potential base-case process efficiencies such as product recovery and solvent use. 
For this conceptual continuous flowsheet, continuous extraction operations were investigated for 
Table 3. Temperature-conversion-selectivity data for photo-oxidation of 2 (DHAA) into 
intermediates 3, 4 and 5 (Seeberger et al., 2014). 
 
Temperature Conversion (%) Selectivities (%) 
(°C) X2 S3 S4 S5 Sother 
−18 86 82 10 3 5 
0 93 79 11 3 7 
20 92 77 11 5 7 
40 99 73 12 5 10 
75 86 62 10 5 24 
Table 4.  Temperature-yield (based on initial DHAA) data for reaction of 3 into byproducts and API 
1 (a: estimated) (Seeberger et al., 2014). 
 
Temperature Conversiona(%) Yield (%) 
(°C) X2 Y1(API) Y6 Y7 Y10 
−15 49 18.0 1.6 2.1 21.3 
0 63 33.4 3.7 2.1 17.8 
25 78 59.1 6.1 4.4 2.5 
50 67 47.0 7.2 5.5 4.7 
75 55 31.2 7.5 6.1 9.6 
8 
trifluoroacetic acid (TFA) removal.  Firstly, the use of counter-current extraction was investigated; 
however, the low initial amounts of TFA (approximately 2.5 mole %) and tie-line behaviour of the 
calculated TFA-toluene-water ternary phase diagram implies that this is impractical.  Instead, the 
potential of a continuous two-phase agitated tank with subsequent phase settling and separation was 
investigated.  In this idealised design, the dispersed organic phase (toluene) is injected into the 
continuous phase (water-NaHCO3 solution) with agitation from an impeller.  As acid-base reactions 
are almost instantaneous, with rate constants over the order of 108 s−1 reported (Pines et al., 1997), 
given sufficient bulk mixing the reaction should then be limited by the rate of mass transfer of TFA 
from the dispersed organic (toluene) droplets to the continuous water phase, which can be represented 
using the following equation: 
 WTFAWTFAWTFA CCAKN ,* .   (2) 
Where ṄTFA is the molar transfer rate of TFA, A΄ is the interfacial area (between dispersed organic 
drops and bulk aqueous phase), CTFA,W is the concentration of TFA in the aqueous phase, and C
*
TFA,W 
is CTFA,W at equilibrium.  The overall mass transfer coefficient KW is calculated from the organic- and 
water-side film transfer coefficients kO (from dispersed phase Sherwood number Shd) and kw (from the 
continuous phase Sherwood number, using the Skelland-Moeti correlation) (Skelland and Moeti, 
1990): 
WOW kmkK
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Here, DTFA,O/W is the diffusivity of TFA in toluene (O) or water (W), d32 is the Sauter mean droplet 
diameter (of the dispersed toluene droplets), ScW and FrW are respectively the Schmidt and Froude 
numbers of the continuous phase, Eo is the Eotvos number, φ is the dispersed phase volume fraction, 
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Fig. 5.  Mass balance of key flowsheet streams (g hr−1). 
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Rei is the impeller Reynolds number, Di and Dt are respectively the impeller and tank diameters.  As 
TFA is miscible in both toluene and water, the partition coefficient m is unity.  Equation (1) can then 
be used to estimate the potential for TFA extraction by varying parameters including φ and tank 
dimensions and operation. 
In published examples, following batch acid extraction, toluene is removed by evaporation under 
reduced pressure, with the resultant solid dissolved in acetonitrile and then refluxed with activated 
carbon, which is then filtered off; this removes DCA.  The solvent is then again evaporated off under 
reduced pressure; the solid proceeds to recrystallisation steps using cyclohexane and ethanol. 
Although effective at recovering and purifying the API in the lab, alternatives to this procedure are 
required for industrial scale CPM use.  In batch pharmaceutical production, solvent swaps are 
frequent due to their varying suitability in different applications; the best solvent for a reaction may 
not be suitable for a subsequent operation.  However, solvent swaps are costly in terms of energy and 
material waste, and also take time.  Another benefit of continuous production is that, almost 
exclusively, a single primary solvent is used (except where separations are required, e.g. liquid-liquid 
extraction, or anti-solvents for crystallisation).  Here, we investigated the potential for toluene to be 
kept as a solvent, and an anti-solvent introduced, to replace the batch recrystallisation procedures 
using cyclohexane and ethanol.  The UNIFAC method for estimating activity coefficients was used 
toward calculating artemisinin solubilities (see Appendix) (Gracin et al., 2002). 
5 RESULTS AND DISCUSSION 
5.1 Mass balance and reactor design 
The continuous design presented here produces artemisinin at a rate of 17.66 g hr−1, corresponding to 
141.28 kg annual production (prior to separation) for 8,000 annual operating hours.  A summary of 
key flowsheet stream mass balances is illustrated in Fig. 5.  The mass balances are based on published 
kinetics and conversions for the reactions (Kopetzki et al., 2013; Seeberger et al., 2014). 
The experimental demonstration achieved recoveries of 87.7% and 80.7% in the recrystallisation 
stages, for an overall product recovery of 70.8% (although it is reported that marginally higher 
recoveries are attainable) (Seeberger et al., 2014).  Assuming that similar performance can be 
achieved by scaling up the batch scheme to mass flows used here, this recovers 12.5 g hr−1, or 100.0 
kg per year of API.  The mass flow to this point has been used as a preliminary level to produce this 
benchmark annual quantity of API, allowing subsequent evaluation of continuous separation 
operations with regards to mass flows required. 
Toluene (C7H8) is the organic solvent.  The key species are feedstock 2 (DHAA), intermediate 3, 
and 1 (artemisinin, the API product).  In addition to these key organic molecules, various byproducts 
are present: species 4 and 5 are produced alongside 3 (although at far lower selectivity), while 7 and 
10 also originate from 3.  TFA acts as acid catalyst here, and so is never consumed.  DCA, the 
photosensitizer, is present in quantities too low to display in Fig. 5. 
Small sizes have been calculated for the two reactors, with 19.722 mL for PFR1 and 78.923 mL for 
PFR2 (Table 5).  Small internal diameters of 5.0 mm were studied to ensure that there is excellent 
heat and mass transfer.  CPM pilot plant systems have been successfully demonstrated at this scale, 
with heat transfer ID = 1.6 mm and reactor ID = 11.7 to 40 mm, respectively (Mascia et al., 2013). 
Process simulations have also been performed at the reported capacity and compared to the published 
reactor dimensions implemented in the laboratory-scale experimental system (Kopetzki et al., 2013).  
These reactor sizes are for the production capacity presented in Fig. 5: larger capacities will require 
larger reactors, assuming one system is used. 
Table 5. PFR design results. 
 
PFR # (reaction) 
 
Temperature 
(°C) 
Flowrate 
(g hr−1) 
Conversion 
(%) 
ID 
(mm) 
Volume 
(mL) 
Length 
(mm) 
PFR 1 (2 → 3) −20 207.48 98.0 5.0 19.722 1005 
PFR 2 (3 → API) 25 207.48 83.5 5.0 78.923 4020 
           (4 → 6) 25 207.48 67.0 5.0 78.923 4020 
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Kopetzki et al. (2013) report an overall yield of 65% for artemisinin, which is close to the value 
calculated here (63.5%).  More detailed experimental investigations for the full continuous process 
will elucidate the contributing factors to this small variation: as stated previously, in the full 
experimental demonstration toluene is used as a solvent with DCA as photosensitizer, while the value 
of 63.5% was computed on the basis of the marginally lower performance of DCM and TPP (solvent 
and photosensitizer, respectively).  Moreover, the extent to which reactions may occur in the process 
lines between reactors is not taken into consideration here.  While this is expected to be minimal, 
Kopetzki et al. (2013) do have an additional small pre-heating line at 10°C between the two reactors. 
In the demonstration of the continuous chemical synthesis the reaction line was coiled around a 
transparent plate and placed near a mercury lamp (Kopetzki et al., 2013).  The optimal configuration 
for maximum energy efficiency could be different, and multiple options are possible, including 
wrapping the reaction line in a coil with the lamp down the centre (Peplow, 2012).  Here, the lamp 
along with exact configuration of the reactor are assumed to provide the necessary light for the 
photooxidation reaction. 
5.2 Final separation 
The product stream F10 requires separation and purification of the API product, artemisinin (1).  The 
batch scheme utilised in the demonstration of the continuous chemical synthesis is illustrated in Fig. 
6, where flows SF1 - SF18 are not true streams but illustrate the use and movement of material to and 
from stages; SF1 corresponds to the effluent stream of PFR2, which is CPM flowsheet stream F10.  An 
extraction with aqueous sodium bicarbonate first removes trifluoroacetic acid (TFA); this is followed 
by washing with brine and water.  The organic phase then proceeds to a solvent removal stage where 
toluene is removed: this consists of drying with sodium sulfate, concentration using reduced pressure, 
followed by acetonitrile addition and subsequent evaporation and then vacuum drying.  The resulting 
solid is then dissolved in acetonitrile with added activated carbon (which captures poorly soluble 
DCA) and filtered, which removes the carbon (along with DCA).  The filtration product is then 
recrystallised using cyclohexane and ethanol in multiple steps, resulting in the API product in solid 
form (Kopetzki et al., 2013; Seeberger et al., 2014).  These operations are suitable for lab scale 
1
Extraction x2
(remove TFA)
2
Solvent removal
(remove tol.)
3
Dissolve/filter
(remove DCA)
SF1
(PF2 effluent)
(F10)
SF2
NaHCO3(aq)
SF4
SF3
Aq phase
SF5
Toluene
SF6
SF7
Acetonitrile
SF8
DCA
SF9
SF11
Waste
SF10
Cyclohexane/Ethanol
5
Crystallisation
80.7% recov.
SF15
SF14
Waste
SF13
Cyclohexane/Ethanol
SF124
Crystal./wash
4 steps
87.7% recov.
4.2
Crystallisation
4.3
Wash + dry
4.1
Crystallisation
Cyclohexane/Ethanol
Cyclohexane
SF12SF9
Cyclohexane
Org waste
4.4
Wash(×3) + dry
Cyclohexane
Drying
6
Wash(×2)
SF16
Cyclohexane
SF17
Waste
SF18
Artemisinin
 
Fig. 6. Batch separation scheme for artemisinin purification according to the original flow synthesis method 
considered (Kopetzki et al., 2013). 
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purification (where such steps are known as workup), but implementation of the continuous scheme in 
production scale requires continuous alternatives. 
For the continuous extraction of TFA form the organic phase, the use of an agitated tank was 
investigated, where the organic phase (toluene) is dispersed into the aqueous phase.  Sodium 
bicarbonate, saturated in the aqueous phase, neutralises the TFA.  Oxygen and any other gaseous 
components are assumed removed prior to this by simple venting, with the process now at 
atmospheric pressure.  Adjustable parameters affecting the estimation of TFA molar mass transfer 
from the toluene to the water include the impeller speed (set a high but attainable 15 rev/s), impeller 
diameter, tank diameter (two or three times the impeller diameter) and dispersed phase volume 
fraction (set with an upper limit of 0.2). 
The inlet flow of TFA at this point in the flowsheet (entering an agitated tank) is 49.3 mmol hr−1 
(Fig. 7, black dashed line).  As illustrated by Fig. 7, mass transfer of TFA is favoured by higher 
dispersed phase volume fractions and impeller sizes (illustrated here by tank volumes, which are tied 
to impeller dimensions).  Naturally, there are practical limits to both of these, particularly the volume 
fractions.  Furthermore, higher ratios of impeller diameter to tank diameter (Fig. 7B) result in higher 
required volumes for a given mass transfer rate; however, smaller impellers do tend towards higher 
A: Dt = 2Di B: Dt = 3Di 
  
Fig. 7. Variation of potential mass transfer of TFA with tank volume and dispersed phase (organic) volume 
fraction (φ).  A: Tank diameter (Dt) 2 times the impeller diameter (Di).  B: Tank diameter (Dt) 3 times the 
impeller diameter (Di). 
 
Fig. 8.  Generalised schematic for continuous separation. 
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energy efficiency. 
Eight common solvents, many classed as desirable (with the lowest toxicity and environmental 
impact) by a solvent selection guide, were initially investigated as for potential antisolvents for use in 
a continuous crystallisation operation: ethanol (EtOH), acetone, ethyl acetate (EtOAc), methanol 
  
  
  
  
  
Fig. 9.  Artemisinin solubility evaluation of potential anti-solvents for continuous crystallisation using the 
UNIFAC activity coefficient prediction method.  Solvents appear in order of decreasing API solubility.  The 
vertical axis is in units of mole fraction. 
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(MeOH), 2-propanol (2-PrOH), n-butanol (n-BuOH), butanone (methyl ethyl ketone, MEK) and 
acetonitrile (ACN).  All three are miscible with toluene, yet have a lower solubility of API.  
Artemisinin solubilities were evaluated for a temperature range of 0 to 40°C, for toluene-to-anti-
solvent ratios of 50:50, 30:70, and 20:80 by weight (Fig. 9).  An illustrative, generalised scheme of 
the design described here is given in Fig. 8. 
Solubility increases with temperature in each case, while some candidate anti-solvents (Acetone, 
EtOAc, MEK) show little solubility variation between different solvent-to-anti-solvent ratios.  
Additional ratios, with toluene in the majority, were also studied, however in these cases anti-solvent 
addition increased predicted artemisinin solubilities, likely due to toluene being non-polar (results not  
shown).  The use of ethyl acetate (EtOAc) is predicted to produce the lowest artemisinin solubilities.  
Recently published experimental solubility data for the toluene-ethanol system implies that the values 
computed through UNIFAC here are an over-prediction (Horváth et al., 2015).  The complex 
molecular structure of artemisinin, along with the unavailability of some group interaction parameters, 
 
Fig. 10.  Conceptual crystallisation operating parameters; empirical solubility data has been used (Horváth et al., 
2015).  System assumed to be composed of solute (API), solvent (toluene), and anti-solvent (EtOH) only. 
 
Fig. 11.  Conceptual crystallisation operating parameters; calculated using the UNIFAC method – see Fig 8. 
EtOAc.  System assumed to be composed of solute (API), solvent (toluene), and anti-solvent (EtOAc) only. 
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are plausible explanations for this discrepancy.  For further design, the experimental solubility data 
from Horváth et al. (2015) were used, employing ethanol as antisolvent with suitable feed API 
concentrations studied for each case of antisolvent amount (90% of saturation, or 26.8%, 18.9%, and 
14.1% by mass for 50:50, 30:70 and 20:80 of toluene : EtOH, respectively) (Fig. 10).  This was 
compared with the use of ethyl acetate (EtOAc) as anti-solvent, studying similar feed API 
concentrations of (90% saturation, or 26.2%, 25.2% and 24.4% by mass (for 50:50, 30:70 and 20:80 
of toluene : EtOAc, respectively) using solubility data calculated via the UNIFAC method (Fig. 11). 
Stream concentration to lower solvent amount is required for efficient crystallisation: antisolvent 
addition without API concentration results in low feed API mass percentages with which 
crystallisation cannot be performed (i.e. concentration is below the solubility that would be reached at 
the bottom of the temperature range).  In order to achieve the desired feed API concentrations, anti-
solvent must first be added, as toluene evaporation alone will exceed API saturation (Liu et al., 2009).  
The required anti-solvent quantities to be added prior to evaporation in each case were calculated by 
performing isothermal flash calculations in the UniSim® software package (Honeywell, 2014).  The 
predicted solubilities achieved from the use of ethyl acetate (Fig. 11) are higher than experimental 
solubilities for ethanol use (Fig. 10), however there is less variation with quantity of antisolvent. 
Table 6.  Comparison of batch vs. continuous API recovery: EtOH anti-solvent.  
      
  Batch  CPM  
   1 2 3 
Production capacity 
(kg year−1) 
 100 100 100 100 
PFR outflow (g hr−1) 2 (DHAA) 0.47 0.61 0.51 0.51 
 3 17.66 23.30 19.49 19.17 
 1 (API) 5.62 7.41 6.20 6.10 
 TFA 5.09 6.71 5.61 5.52 
 O2 3.70 4.89 4.09 4.02 
 4 1.04 1.37 1.14 1.13 
 5 0.80 1.06 0.88 0.87 
 6 1.53 2.01 1.68 1.66 
 7 1.09 1.44 1.20 1.18 
 10 0.66 0.87 0.73 0.72 
 H2O2 0.16 0.21 0.17 0.17 
 H2O 1.28 1.69 1.42 1.39 
      
Solvent (g hr−1) Toluene 168.27 221.95 185.65 182.61 
Solvent : antisolvent 
(weight : weight) 
 - 50:50 30:70 20:80 
Separation ( g hr−1) ACN 19.80 - - - 
 Cyclohexane 587.80 - - - 
Antisolvent ( g hr−1) EtOH 18.60 56.65 107.02 189.53 
 EtOAc - - - - 
      
Thermodynamic API 
recovery (%) 
 70.1 53.7 64.1 65.2 
      
Waste (g hr−1) API 5.16 10.80 6.99 6.67 
 
Unrecovered 
solvents 
794.51 253.84 244.11 276.17 
 Others (excl. O2) 16.35 21.57 18.04 17.75 
 Total 816.03 286.21 269.14 300.58 
E-factor  65.28 22.90 21.53 24.05 
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The API recovery that could be achieved was assumed to be the thermodynamically possible yield 
for each system, and on this basis the three continuous separation schemes (varying antisolvent use, 
for a temperature drop from 40°C in the feed to 5°C) for anti-solvent (ethanol and ethyl acetate) were 
compared with the experimentally employed batch scheme (Table 6 and Table 7, respectively).  
Annual operation was again assumed to be 8,000 hours. 
Maximum product recoveries improve with increasing antisolvent use in the case of ethanol 
(between 53.7% to 65.2%), in contrast to ethyl acetate, for which they remain relatively constant 
(between 57.2% to 58.8%) (Figure 12); this is predominantly due to the solubility behaviour of the 
API in the antisolvent-solvent mixture.  While ethanol is preferable based on product recoveries, 
taking into account additional metrics, particularly those related to environmental impact and safety, 
can significantly affect antisolvent preferability (Jolliffe and Gerogiorgis, 2016). 
Varying product recoveries with rate of antisolvent use offer potential for process control.  API 
productivity could be increased or maintained by adjusting the rate of antisolvent use if there were 
bottlenecks elsewhere in the process in terms of absolute mass throughput. 
Table 7.  Comparison of batch vs. continuous API recovery: EtOAc anti-solvent. 
      
  Batch  CPM  
   4 5 6 
Production capacity 
(kg year−1) 
 100 100 100 100 
PFR outflow (g hr−1) 2 (DHAA) 0.47 0.58 0.57 0.56 
 3 17.66 21.86 21.65 21.27 
 1 (API) 5.62 6.95 6.89 6.77 
 TFA 5.09 6.30 6.24 6.13 
 O2 3.70 4.58 4.54 4.46 
 4 1.04 1.28 1.27 1.25 
 5 0.80 0.99 0.98 0.97 
 6 1.53 1.89 1.87 1.84 
 7 1.09 1.35 1.34 1.31 
 10 0.66 0.82 0.81 0.80 
 H2O2 0.16 0.20 0.19 0.19 
 H2O 1.28 1.59 1.57 1.55 
      
Solvent (g hr−1) Toluene 168.27 208.21 206.25 202.65 
Solvent : antisolvent 
(weight : weight) 
 - 50:50 30:70 20:80 
Separation ( g hr−1) ACN 19.80 - - - 
 Cyclohexane 587.80 - - - 
Antisolvent ( g hr−1) EtOH 18.60    
 EtOAc  30.72 44.90 52.84 
      
Thermodynamic API 
recovery (%) 
 70.1 57.2 57.7 58.8 
      
Waste (g hr−1) API 5.16 9.36 9.15 8.77 
 
Unrecovered 
solvents 
794.51 238.92 251.15 255.49 
 Others (excl. O2) 16.35 20.24 20.04 19.69 
 Total 816.03 268.51 280.34 283.96 
E-factor  65.28 21.48 22.43 22.72 
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5.3 Environmental impact (E-factor) 
A useful metric for quantifying environmental impact is the E-factor (Sheldon, 2012).  It is versatile 
with multiple definitions, the simplest of which is the quantity of waste generated per unit of product, 
in mass terms. Sustainability metrics (Balomenos et al., 2014) and systematic model-based sensitivity 
analyses (Angelopoulos et al., 2013, 2014) acquire ever-increasing importance in the entire spectrum 
of chemical process industries, in order to assess profitability in tandem with environmental and 
societal responsibility. Highly efficient industries relying almost completely on continuous production 
techniques – such as oil and gas – have E-factors in the order of 0.1, while batch-reliant processes 
such as pharmaceutical production generate significant relative amounts of waste with high E-factors 
of 200 not uncommon (Ritter, 2013).  Here, the E-factor is computed where the product is (pure) 
recovered API, while the waste consists of byproducts (bpd), unconverted reactants (ur), waste 
solvent (ws, all assumed unrecovered), and unrecovered API (uAPI): 
API
uAPIwsurbpd
API
waste
m
mmmm
m
m
E

  (6) 
Material requirements for TFA removal have not been included in E-factor calculations as water is 
the main component in this stage, and due to its negligible environmental impact cost is commonly 
excluded (Sheldon, 2012).  Moreover, this operation is upstream of the subsequent API separation and 
general E-factor trends would remain unaffected.  The solvents have been assumed to be unrecovered, 
while unused O2 has been assumed to have been recovered via simple phase separation after exiting 
the last reactor. 
For the batch scheme outlined in Fig. 6, the calculated E-factor is 65.28: for every kilogram of API 
pure API obtained, 65.28 kilograms of waste are generated.  This is very likely an underestimation, as 
specific quantities of chemical used were not available for all of the operations detailed in Fig. 6 
(Seeberger et al., 2014).  Solvents form the bulk of the waste (794.5 g/hr). 
Based on the assumed feed concentrations (post-solvent evaporation), calculated E-factor values 
are better (lower) for the six studied CPM scenarios in comparison to the batch case, ranging from 
21.48 to 24.05 (Table 6, Table 7, Fig. 12).  This implies that for a unit of API produced, the CPM 
schemes generate on average 66.2% less waste than the batch process.  While high compared to 
industries exclusively using continuous processes, these values are acceptably low given that typical 
pharmaceutical processes have significantly worse values.  Although product recoveries are lower for 
the CPM cases than the batch case (CPM: 53.7-64.1%, batch: 70.1%), this is offset by the significant 
reduction in waste.  Moreover, it must be noted that the separation scheme employed would not be 
implemented industrially: while high recoveries are achieved, the required timescale of the batch 
 
Fig. 12.  Evaluation of batch and continuous separation schemes: API recovery and E-factor. 
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operations was not a consideration, with maximum product recovery the goal.  In addition, although 
material requirements are likely to change and E-factors worsen with more detailed design of CPM 
separation cases, they nevertheless show promise, and it is unlikely that only a single crystallisation 
stage would be employed.  Additional stages or other separation technologies can be used to greatly 
enhance performance (Horváth et al., 2015). 
The differences between E-factors calculated for the use of ethanol (Table 6) or ethyl acetate (Table 
7) are small, ranging from 21.43-24.05 and 21.48-22.72, respectively, an average difference of only 
2.7%.  The use of ethanol results in higher API recoveries, with the exception of 50:50 toluene : 
ethanol use.  Product recoveries increase with anti-solvent use: for both antisolvents, recovery is 
lowest for 50:50 toluene : antisolvent and highest for 20:80.  Due to the smaller influence of 
antisolvent quantity on API solubility (Fig. 10), there is less variation in recovery when ethyl acetate 
is used. 
Given the similar performances of the two antisolvents studied here, additional factors such as 
compatibility with subsequent (or additional prior) separation operations require investigation for 
accurate evaluation.  Nevertheless, on the basis of the calculations and analysis presented here, the use 
of ethanol in a 20:80 ratio with toluene by weight (CPM case 3, Fig. 12) is to be favoured: it results 
in the highest API recoveries, while the E-factor (i.e. waste generated) is only marginally more than 
the other CPM cases, but significantly less than the batch case. 
6 CONCLUSIONS 
The Continuous Pharmaceutical Manufacturing (CPM) of the key antimalarial substance artemisinin 
has been presented in this paper.  Multiple designs with different continuous product recoveries have 
been compared with a batch reference case, with all designs producing 100 kg of API per year.  The 
chemistry this study is based on is of particular interest due to the feedstock being a waste product of 
current artemisinin production: significant added value is possible from implementing this design 
alongside established artemisinin production plants. 
Employing published reaction data novel kinetic data analysis and parameter estimation have been 
performed, allowing the computation of small reactor volumes (19.72 mL and 78.72 mL) have been 
computed based on published reaction data, implying capital cost and space advantages which are 
hallmark benefits of continuous production. 
An environmental (E-) factor of 65.28 has been estimated for a reference case design studying 
reported performances of a batch separation scheme, an acceptable value for a process employing 
some batch operations.  Evaluations of potential continuous alternatives, using published solubility 
data as well as the UNIFAC method, indicate good performance with improved E-factors ranging 
from 21.48 to 24.05, with ethanol and ethyl acetate good anti-solvent candidates in a crystallisation 
process; the small decrease in product recovery for continuous separation (70.1% for batch, up to 
65.2% for continuous designs) is offset by significantly reduced waste production compared to the 
batch process. Investigation of a continuous alternative for acid neutralisation illustrates the scope for 
using continuous agitated tanks. 
Artemisinin is a substance of critical importance.  An effective anti-malarial itself, it is the 
precursor to many anti-malarial derivatives which are widely used to combat a disease of significant 
impact.  The use of a current waste material for feedstock gives significant added value to the 
implementation of this design, which is an excellent opportunity for demonstrating CPM benefits.  
The potential use of a widely used solvent of low toxicity and environmental impact in a continuous 
alternative separation illustrates how green processing ideals can be met with systematic design.  To 
further demonstrate the potential of this design, a full investigation of an integrated continuous 
separation process is required; this is of particular importance for downstream processing. 
The need and benefits of full process simulations of this design, which have been technically and 
economically optimised, emerges from this study.  The use of a systematic framework and design 
methods will be of paramount importance in continuing to build the case for CPM. 
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NOMENCLATURE 
Latin Letters 
A’ Interfacial area, m2 
as Pure solid component activity 
CA Concentration of molecule A, mol L−1 
C*A Equilibrium concentration of molecule A, mol L−1 
CA,0 Initial concentration of molecule A, mol L−1  
CA,W Aqueous phase concentration of molecule A, mol L−1  
CP Specific heat capacity at constant pressure, J mol−1 K−1 
d32 Sauter mean droplet diameter, m 
DA,O/W Diffusivity of molecule A in organic/aqueous phase, m2 hr−1 
Di Impeller diameter, m 
Dt Tank diameter, m 
E Environmental factor, dimensionless 
Eo Eotvos number, dimensionless 
FrW Aqueous (continuous) phase Froude number, dimensionless 
ID Internal diameter, mm 
k’ Pseudo-first-order reaction rate constant, hr−1 
ki Rate constant of reaction i, L mol−1 hr−1 (second-order reaction) 
kO Organic phase film mass transfer coefficient, m hr−1 
kW Aqueous phase film mass transfer coefficient, m hr−1 
KW Overall mass transfer coefficient, m hr−1 
Li UNIFAC compound parameter of r, q and z  
mAPI Mass of recovered API 
mbpd Mass of byproducts 
mur Mass of unconverted reactants 
mws Mass of waste solvent 
muAPI Mass of unrecovered API 
MW Molecular weight, g mol−1 
mwaste Mass of waste 
ṄTFA Molar rate of trifluoroacetic acid transfer (mmol hr−1) 
Qk UNIFAC surface area parameter for functional group k  
qi UNIFAC parameter for molecule i, a measure of Van der Waals molecular surface area 
R Universal gas constant, 8.3144 J mol−1 K−1 
Rei Impeller Reynolds number, dimensionless 
Rk UNIFAC volume parameter for functional group k  
rA Rate of reaction of molecule A, mol l−1 s−1 
ri UNIFAC parameter for molecule i , a measure of Van der Waals volume 
Si Selectivity of species i 
ScW Aqueous (continuous) phase Schmidt number, dimensionless 
Shd Organic (dispersed) phase Sherwood number, dimensionless 
ShW Aqueous (continuous) phase Sherwood number, dimensionless 
T Temperature, K 
Tfus Melting (fusion) point temperature, K 
t Time, hr 
Umn UNIFAC energy interaction between groups m and n  
XA Conversion of molecule A at time t  
XA,f Final conversion of molecule A  
xi Mole fraction of molecule i 
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xm UNIFAC mole fraction of group m 
xi 
sat Mole fraction at saturation (solubility) 
Yi Yield of species i 
z UNIFAC system coordination number (default value: 10) 
Greek Letters 
Γk UNIFAC residual group activity coefficient for group k 
Γk
(i) UNIFAC residual group activity coefficient in a reference solution of 100% i molecules 
γi Activity coefficient of component i 
γi 
c UNIFAC combinatorial component of 𝛾𝑖  
γi 
r UNIFAC residual component of 𝛾𝑖  
γi 
sat Activity coefficient of component i at saturation 
ΔHfus Enthalpy of fusion, J mol−1 
θi UNIFAC molar-weighted area fractional component for molecule i  
θm UNIFAC summation of area fraction of group m over all different groups  
νk 
(i) UNIFAC number of occurrences of functional group k in molecule i 
φ Dispersed phase volume fraction 
τi Residence time in reactor i, hr 
ϕi UNIFAC molar-weighted segment fractional component molecule i 
Ψmn UNIFAC group energy interaction parameter 
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APPENDIX 
Solubility 
The solubilities (saturation mole fractions, satix ) of components in solvent mixtures are calculated 
using the following equation (Gracin et al., 2002): 
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Hfus is the enthalpy of fusion and Tfus is pure solid solute i melting point.  Solid activity (
s
ia ) is first 
estimated via the exponential portion of Eq. (A1).  Activity coefficient sati  is obtained from Eq. 
(A2) when then allows the calculation of satix  via Eq. (A1).  An iterative process is required for Eq. 
(A1), as the activity coefficient sati  also depends on mole fraction 
sat
ix . 
In the UNIFAC method the activity coefficient for molecule i ( i ) is the sum of a combinatorial 
and residual components ci  and 
r
i , respectively (Fredenslund et al., 1975): 
r
i
c
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(A2) 
The UNIQUAC model is used to compute ci  (Abrams and Prausnitz, 1975): 
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In equation A2 i  is the molar weighted segment fractional component and i  is the area fractional 
component: 
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The UNIFAC compound parameter Li is defined by ri , qi and z: 
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Parameters ir  and iq , also used in computing i  i , are calculated from volume ( R ) and surface 
area ( Q ) parameter contributions from functional groups: 
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where k  is the number of occurrences of group k  on a molecule. 
The residual component ri  is calculated from k  and 
 i
k , the residual group activity coefficient 
of group k in reality and in a reference solution of pure substance i, respectively: 
     
k
i
kk
i
k
r
i lnlnln   (A9) 
Both k  and 
 i
k  are calculated via the following equation: 
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where parameters m  and xm (summation of the area fraction of group m over all different groups, and 
the mole fraction of group m, respectively) are defined as follows: 
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A modified Arrhenius equation is used to calculate mnΨ  (a measure of interaction energy between 
groups): 

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Tables for group interactions and other parameters are widely available in literature (Wittig et al., 
2003). 
 
